31 July - Wednesday

Preliminary program - subject to change.

09:00 - 10:00

Plenary Lecture: Drug Metabolism, Pharmacogenomics and the Quest to Personalize HIV Treatment and Prevention
View the abstract of this lecture.

Namandjé Bumpus, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

10:00 - 10:30

Refreshment Break with Exhibitors and Posters

10:30 - 12:30

Concurrent Sessions: Symposia 9 and 10

Symposium 9: Role of Albumin in Drug Disposition Revisited
Co-Chairs: Malcolm Rowland, University of Manchester, Manchester, United Kingdom and Stephen Hall, Eli Lilly and Company, Indianapolis, Indiana, USA
View the Symposium 9 speaker abstracts.

Albumin-mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates
Yuichi Sugiyama, Sugiyama Laboratory, RIKEN Baton Zone Program, RIKEN, Yokohama, Kanagawa, Japan

Effects of Albumin on Prediction of Liver Kpuu and Human Hepatic Clearance for Enzyme- and Transporter-Mediated Mechanisms
Li Di, Pfizer Inc., Groton, Connecticut, USA

Impact of Albumin and Plasma on the Renal Uptake of OAT1 Substrates
Roos Masereeuw, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands


Symposium 10: Ontogeny of Enzymes and Transporters and their Implications in Pediatric PBPK Modeling to Inform Pediatric Dosing

Co-Chairs: J. Steven Leeder, Children's Mercy Hospital, Kansas City, Missouri, USA and Ping Zhao, Bill & Melinda Gates Foundation, Seattle, Washington, USA
View the Symposium 10 speaker abstracts.

Ontogeny of Human Membrane Transporters: from Data to Application
Saskia de Wildt, Radboud University Medical Center, Nijmegen, Netherlands

Pediatric PBPK: Dealing with Uncertain Parameters and Deciding on Success Criteria for Predictability
Trevor Johnson, Certara UK Limited (Simcyp Division), Sheffield, United Kingdom

Use of ‘Virtual Children’ to Inform Exposure-Controlled Dosing of Drugs in Children
Jean Dinh, Children's Mercy Hospital, Kansas City, Missouri, USA

Building, Verifying and Validating Pediatric PBPK Models: Vulnerabilities and Knowledge Deficits
Ping Zhao, Bill & Melinda Gates Foundation, Seattle, Washington, USA

Lunch, Visit Exhibitors, Poster Presentations, and Exhibitor Showcase
12:30 - 14:30 Poster Presentations Sponsored by
COVANCE
13:15 - 13:45 Exhibitor Showcase Sponsored by
PHARMARON

12:30 - 14:30

COVANCE Poster Session
Poster presentations are an integral part of all ISSX meetings. Don’t miss this opportunity to view the abstract posters and interact with attendees.

PHARMARON Exhibitor Showcase
The Exhibitor Showcase talks have been approved for presentation at our meeting. All attendees are invited to attend these sessions in the exhibit hall.

ISSX Awards Presentations and Lectures

14:30 - 16:00

16:00 - 18:00

Plenary Symposium 11

Symposium 11: ‘War Stories’ – ADME Issues Encountered and Addressed in Drug Discovery and Development
Co-Chairs: Marcel Hop, Genentech Inc, South San Francisco, California, USA and Deepak Dalvie, Celgene, San Diego, California, USA
View the Symposium 11 speaker abstracts.

Navigating through Discovery and Development Painlessly: Snapshots within the Nav1.7 Program
Jae Chang, Genentech Inc, South San Francisco, California, USA

Elagolix: A Mechanistic Understanding of Drug-Drug Interactions
David Stresser, Abbvie, Chicago, Illinois, USA

ZEPATIER: The Tale of Two Novels
Christine Fandozzi, Merck & Co. Inc., USA

Management of MIST in a Case of Multiple Metabolic Species Differences
Lars Weidolf, AstraZeneca R & D, Mölndal, Sweden

18:00 - 18:30

Closing Session